Detalles de la búsqueda
1.
The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study.
Cancer Immunol Immunother
; 63(2): 147-60, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24233343
2.
Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial.
Int J Cancer
; 132(7): 1581-91, 2013 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22948952
3.
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.
J Transl Med
; 11: 88, 2013 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-23557172
4.
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.
Proc Natl Acad Sci U S A
; 107(26): 11895-9, 2010 Jun 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-20547850
5.
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
N Engl J Med
; 361(19): 1838-47, 2009 Nov 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-19890126
6.
A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.
Cancer Immunol Immunother
; 61(9): 1485-92, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22684521
7.
Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer.
Clin Cancer Res
; 15(3): 1086-95, 2009 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19188184
8.
Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.
Clin Cancer Res
; 22(10): 2342-50, 2016 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26813357
Resultados
1 -
8
de 8
1
Próxima >
>>